Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an announcement.
Prescient Therapeutics Limited has announced the quotation of 11,250,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from August 27, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its strategic initiatives in the biotechnology sector.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in creating targeted and personalized medicine solutions to improve cancer treatment outcomes.
Average Trading Volume: 1,311,111
Technical Sentiment Signal: Sell
Current Market Cap: A$42.65M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.